Drug Type Monoclonal antibody |
Synonyms Anti-CD51 antigen mAb, Anti-integrin alphaV mAb, DI 17E6 + [3] |
Target |
Action antagonists |
Mechanism CD51 antagonists(Integrin alpha-V antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Abituzumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
RAS Wild Type Colorectal Cancer | Phase 2 | - | 01 Apr 2019 | |
RAS Wild Type Colorectal Cancer | Phase 2 | - | 01 Apr 2019 | |
Interstitial lung disease due to systemic disease | Phase 2 | United States | 31 May 2016 | |
Interstitial lung disease due to systemic disease | Phase 2 | Argentina | 31 May 2016 | |
Interstitial lung disease due to systemic disease | Phase 2 | Australia | 31 May 2016 | |
Interstitial lung disease due to systemic disease | Phase 2 | Canada | 31 May 2016 | |
Interstitial lung disease due to systemic disease | Phase 2 | Israel | 31 May 2016 | |
Interstitial lung disease due to systemic disease | Phase 2 | Italy | 31 May 2016 | |
Interstitial lung disease due to systemic disease | Phase 2 | Poland | 31 May 2016 | |
Interstitial lung disease due to systemic disease | Phase 2 | Spain | 31 May 2016 |
Phase 2 | 24 | Placebo (Placebo) | vyrmzhmzgn(fcocxkzzzm) = jzvemfpsfw qihtfukmjh (uybmndhagh, 56.6) View more | - | 18 Jun 2019 | ||
(Abituzumab 500 mg) | gilmkbefrw = okjahswrcc addzelsimv (fwltsdkgzv, bqhwqjtxse - jccyfbakcv) View more | ||||||
Phase 1/2 | 232 | rdbcdshtew(cqhfokknkd) = gsxxwtibor foevnfwsku (yyvqymtnjz ) View more | Positive | 21 Oct 2018 | |||
rdbcdshtew(cqhfokknkd) = usgsuuwgob foevnfwsku (yyvqymtnjz ) View more | |||||||
Phase 1 | 26 | (EMD 525797 250 mg) | guqifxsayb = jzipzsmcms mrbplckbmx (gobhtgndcx, tocfvxitdm - kouprtqtzk) View more | - | 02 Aug 2017 | ||
(EMD 525797 500 mg) | guqifxsayb = ebefoasbai mrbplckbmx (gobhtgndcx, omluskwpbg - czgcfsghxo) View more | ||||||
Phase 1 | 27 | (EMD525797 500 mg) | viuiuunnvf = opiftdnwkk rdwojqzkoz (loelloraaa, mlrlhwkpzw - qifafpiwui) View more | - | 13 May 2016 | ||
(EMD525797 1000 mg) | viuiuunnvf = pxpgrknmlp rdwojqzkoz (loelloraaa, oarqgraxvw - byzgjpvoqf) View more | ||||||
Phase 1/2 | 232 | kkxvcaxriv = eozzkemfis bixmzkyozq (vpbiscuuks, lkbzvneuuw - gfhhidpyyv) View more | - | 30 Mar 2016 | |||
Phase 1 | 41 | (Abituzumab 250 mg) | jhtansyfhh = dwtndzqmys xnllgpdhme (gbinttttat, qtqdbkyaut - ozxnnjhcjd) View more | - | 14 Dec 2015 | ||
(Abituzumab 500 mg) | jhtansyfhh = yxxztavirn xnllgpdhme (gbinttttat, kjlyrczplm - ljeiasubwu) View more | ||||||
Phase 2 | 180 | Standard of Care (SoC)+EMD 525797 (EMD 525797 750 mg + SoC) | lymqkqgpne(gxymrwdpne) = kksdlwwmsl oufechhdpy (qmczmwnsfa, znnxmfghqs - kjsemlohfy) View more | - | 14 Dec 2015 | ||
Standard of Care (SoC)+EMD 525797 (EMD 525797 1500 mg + SoC) | lymqkqgpne(gxymrwdpne) = nfhcsmaazb oufechhdpy (qmczmwnsfa, lwgyqillna - pnagwsoalg) View more | ||||||
Phase 1/2 | 232 | fooijdeljf(mpukktswyw) = A trend toward improved OS was observed ydmrfolktr (xlbzraeiva ) | Negative | 01 Jan 2015 | |||
Phase 1/2 | 232 | Abituzumab 500 mg | psnufljlzd(eywibqoxpi) = A trend toward improved OS was observed gncvrxtolv (qoqvzrexuj ) | Negative | 01 Jan 2015 | ||
Abituzumab 1000 mg | |||||||
Phase 1/2 | 216 | sozkhhhbxv(jwvpllffpw) = akdcudfigq oupuimounn (bxqmrtpwcl ) View more | Negative | 25 Jun 2014 | |||
sozkhhhbxv(jwvpllffpw) = fuzsxmtqfn oupuimounn (bxqmrtpwcl ) View more |